NCT04988217View on ClinicalTrials.gov

Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

April 15, 2022

Study Completion Date

July 28, 2022

Conditions
Coronavirus Disease 2019
Interventions
DRUG

Interferon-Alpha2B

Nebulized interferon alpha 2B

DRUG

Placebo

Nebulized placebo

Trial Locations (1)

8330033

Red de Salud UC Christus, Santiago

Sponsors

Collaborators (1)

Altum Pharmaceuticals INC
All Listed Sponsors
collaborator

Altum Pharmaceuticals INC

INDUSTRY

lead

Pontificia Universidad Catolica de Chile

OTHER

NCT04988217 - Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19) | Biotech Hunter | Biotech Hunter